Compare HQI & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | RPTX |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.0M | 92.4M |
| IPO Year | N/A | 2020 |
| Metric | HQI | RPTX |
|---|---|---|
| Price | $10.78 | $2.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $13.00 | $3.00 |
| AVG Volume (30 Days) | 56.0K | ★ 1.5M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ 412.84 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $31,691,000.00 | $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,233.33 |
| P/E Ratio | $21.46 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.38 | $0.89 |
| 52 Week High | $15.75 | $2.66 |
| Indicator | HQI | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.43 | 69.29 |
| Support Level | $10.30 | $2.56 |
| Resistance Level | $11.88 | $2.66 |
| Average True Range (ATR) | 0.72 | 0.05 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 73.75 | 77.67 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.